Who is sponsoring NCT00858754?

NCT00858754 is sponsored by Bausch Health Americas, Inc..

What condition does NCT00858754 study?

NCT00858754 studies Opioid-Induced Constipation.

What drugs are being tested in NCT00858754?

Interventions: methylnaltrexone, placebo.

What is the status of NCT00858754?

NCT00858754 is currently WITHDRAWN.

Last reviewed 2019-11-26 · How we verify

A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain

NCT00858754 Phase 4 WITHDRAWN

This purpose of this study is to evaluate the safety and effectiveness of a subcutaneous (injection beneath the skin) form of methylnaltrexone in subjects who have cancer-related pain and constipation from taking opioids. The length of participation will be up to 7 weeks.

Details

Lead sponsor	Bausch Health Americas, Inc.
Phase	Phase 4
Status	WITHDRAWN
Start date	2009-03
Completion	2009-08

Conditions

Opioid-Induced Constipation

Interventions

methylnaltrexone
placebo

Primary outcomes

Bowel movement within 4 hours after the first dose. Collection of adverse events, vital signs measurements, and laboratory assessments. — 1 Day

Countries

United States, Canada, France, Spain